Safety of rasagiline in elderly patients with Parkinson disease.
The authors examined age effects on adverse events from two randomized, controlled trials of rasagiline, comparing younger (younger than 70 years) and older (70 years and older) subjects. Older patients were more prone to serious adverse effects than younger patients, but there was no statistical interaction between age and rasagiline exposure. This absence of an age-rasagiline interaction suggests that rasagiline does not require special safety precautions for elderly subjects with Parkinson disease.
Goetz
C G
CG
Rush University Medical Center, Chicago, IL 60612, USA. cgoetz@rush.edu
Schwid
S R
SR
Eberly
S W
SW
Oakes
D
D
Shoulson
I
I